Relevant bibliographies by topics / Cell Immunotherapy / Journal articles
To see the other types of publications on this topic, follow the link: Cell Immunotherapy.

Journal articles on the topic 'Cell Immunotherapy'

Author: Grafiati
Published: 9 March 2023
Last updated: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Cell Immunotherapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

McKee, Mark, D. "T cell immunotherapy." Frontiers in Bioscience 12, no. 1 (2007): 919. http://dx.doi.org/10.2741/2114.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Sabado, Rachel Lubong, and Nina Bhardwaj. "Dendritic cell immunotherapy." Annals of the New York Academy of Sciences 1284, no. 1 (May 2013): 31–45. http://dx.doi.org/10.1111/nyas.12125.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Osada, Takuya, Timothy M. Clay, Christopher Y. Woo, Michael A. Morse, and H. Kim Lyerly. "Dendritic Cell-Based Immunotherapy." International Reviews of Immunology 25, no. 5-6 (January 2006): 377–413. http://dx.doi.org/10.1080/08830180600992456.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Velardi, Andrea. "NK cell adoptive immunotherapy." Blood 105, no. 8 (April 15, 2005): 3006. http://dx.doi.org/10.1182/blood-2005-01-0322.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Sabado, Rachel L., Sreekumar Balan, and Nina Bhardwaj. "Dendritic cell-based immunotherapy." Cell Research 27, no. 1 (December 27, 2016): 74–95. http://dx.doi.org/10.1038/cr.2016.157.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lee, Jong-Hoon, and Harvey G. Klein. "Mononuclear Cell Adoptive Immunotherapy." Hematology/Oncology Clinics of North America 8, no. 6 (December 1994): 1203–22. http://dx.doi.org/10.1016/s0889-8588(18)30130-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Feldmann, Marc, Carl H. June, Andrew McMichael, Ravinder Maini, Elizabeth Simpson, and James N. Woody. "T-cell-targeted immunotherapy." Immunology Today 13, no. 3 (January 1992): 84–85. http://dx.doi.org/10.1016/0167-5699(92)90146-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Razzak, Mina. "New cell-based immunotherapy?" Nature Reviews Urology 9, no. 3 (February 21, 2012): 122. http://dx.doi.org/10.1038/nrurol.2012.18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bakulesh, Khamar. "Immunotherapy of Bladder Cancer." Cancer Medicine Journal 3, no. 2 (December 31, 2020): 49–62. http://dx.doi.org/10.46619/cmj.2020.3-1020.

Full text
Abstract:
Bladder cancer used to be the only cancer treated by immunotherapy in form of intravesical BCG. Since approval of BCG for Non muscle invasive bladder cancer (NMIBC), there has been significant advancement in our knowledge about immune alteration in cancer and availability of immunotherapeutic agents. Tumor induced cell mediated immunosuppression is identified as a key factor for development and progression of cancer. Immune suppression in bladder cancer is predominantly through Macrophages. Myeloid derived suppressor cell, NK cells, Treg and expression of immune checkpoint receptor inhibitors also contribute to immune suppression. BCG induces innate immune response and its efficacy is limited to NMIBC. Novel immunotherapeutic agents evaluated in bladder cancer are administered locally or systemically to induce innate or adaptive immune response. Systemic administration of antibodies against PD-1/PD-L1 axis are now approved for treatment of locally advanced/metastatic bladder cancer as a first line as well as second line therapy. Pembrolizumab is also approved for BCG unresponsive NMIBC. Since response to immunotherapy are neither uniform nor universal, attempts are made to identify prognostic and predictive biomarkers. Identified biomarkers lack desired specificity and sensitivity. Several immune approaches using innate as well as adaptive mechanism are under evaluation to improve outcome of intravesical BCG or immune check point receptor inhibitors.
APA, Harvard, Vancouver, ISO, and other styles
10

Y, Elshimali. "Chimeric Antigen Receptor T-Cell Therapy (Car T-Cells) in Solid Tumors, Resistance and Success." Bioequivalence & Bioavailability International Journal 6, no. 1 (2022): 1–6. http://dx.doi.org/10.23880/beba-16000163.

Full text
Abstract:
CARs are chimeric synthetic antigen receptors that can be introduced into an immune cell to retarget its cytotoxicity toward a specific tumor antigen. CAR T-cells immunotherapy demonstrated significant success in the management of hematologic malignancies. Nevertheless, limited studies are present regarding its efficacy in solid and refractory tumors. It is well known that the major concerns regarding this technique include the risk of relapse and the resistance of tumor cells, in addition to high expenses and limited affordability. Several factors play a crucial role in improving the efficacy of immunotherapy, including tumor mutation burden (TMB), microsatellite instability (MSI), loss of heterozygosity (LOH), the APOBEC Protein Family, tumor microenvironment (TMI), and epigenetics. In this minireview, we address the current and future applications of CAR T-Cells against solid tumors and their measure for factors of resistance and success.
APA, Harvard, Vancouver, ISO, and other styles
11

Itsumi, Momoe, and Katsunori Tatsugami. "Immunotherapy for Renal Cell Carcinoma." Clinical and Developmental Immunology 2010 (2010): 1–8. http://dx.doi.org/10.1155/2010/284581.

Full text
Abstract:
Immunotherapy plays a significant role in the management of renal cell carcinoma (RCC) patients with metastatic disease because RCC is highly resistant to both chemotherapy and radiation therapy. Many reports illustrate various approaches to the treatment of RCC, such as cytokine-, antigen- or dendritic cell- (DC-) based immunotherapy, and the safety and effectiveness of immunotherapy have been highlighted by multiple clinical trials. Although antitumor immune responses and clinically significant outcomes have been achieved in these trials, the response rate is still low, and very few patients show long-term clinical improvement. Recently, the importance of immune regulation by antigen-presenting cells (APC) and regulatory T cells (Treg cells) has also been discussed. The authors outline the principles of cell-mediated tumor immunotherapy and discuss clinical trials of immunotherapy for RCC.
APA, Harvard, Vancouver, ISO, and other styles
12

Li, Chentao, Ziming Liu, and Yue Zhou. "CAR-T Immunotherapy to Beat Solid Tumors: From Challenges to Improvements." Highlights in Science, Engineering and Technology 8 (August 17, 2022): 54–63. http://dx.doi.org/10.54097/hset.v8i.1110.

Full text
Abstract:
Chimeric antigen receptor T (CAR-T) cell immunotherapy shows potential and guarantee for clinical application in solid tumor treatment, although a section of difficulties must be overcome. Compared with conventional antitumor therapies, the advantages of CAR-T cell treatment include high specificity, great killing power, and long-term effectiveness. But various difficulties in treating solid tumors by CAR-T immunotherapy include intracellular signaling of CARs, immune escape due to antigenic heterogeneity of malignant tumors, physical or cytokine barriers that prevent CAR-T cell entry or limit their persistence, tumor microenvironment of other immunosuppressive molecules, and side effects. This paper describes CAR-T immunotherapy's mechanisms, development, and applications and discusses the status, difficulties, solutions, and future directions of treating solid tumors by CAR-T immunotherapy.
APA, Harvard, Vancouver, ISO, and other styles
13

Khaira Rusdi, Numlil, and Jeanne Adiwinata Pawitan. "Cancer immunotherapy and flow cytometry in immunotherapy monitoring." Biomedical & Pharmacology Journal 12, no. 3 (August 30, 2019): 1587–93. http://dx.doi.org/10.13005/bpj/1789.

Full text
Abstract:
Immunotherapy for cancer treatment continues to be developed and various strategies have been carried out including bioengineering. This endeavour requires development of technology, and efforts to find specific and sensitive tools to monitor immune responses during and after therapy. The purpose of this mini-review was to discuss cancer immunotherapy using T cell and immune checkpoint blockade therapy, as well as immunotherapy monitoring methods using flow cytometry (FCM). Bioengineering of T lymphocytes for immunotherapy and immune checkpoint blockades can be combined with nanoparticles as drug delivery carrier against cancer to increase drug distribution to tumor cells, as well as T cell stimulation regulation to reduce autoimmune effects. In addition, T cell engineering can also prevent Host versus Graft alloreactivity in chimeric antigen receptor (CAR) T cell administration. FCM is a monitoring method that is widely used in pre-clinical and clinical cancer immunotherapy studies.
APA, Harvard, Vancouver, ISO, and other styles
14

Angeles, Christina V., and Michael S. Sabel. "Immunotherapy for Merkel cell carcinoma." Journal of Surgical Oncology 123, no. 3 (February 17, 2021): 775–81. http://dx.doi.org/10.1002/jso.26319.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Nagler, Arnon, and Avichai Shimoni. "Immunotherapy for B-cell lymphoma." Leukemia & Lymphoma 51, no. 1 (January 2010): 7–9. http://dx.doi.org/10.3109/10428190903486238.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Haas, G. P., G. G. Hillman, B. G. Redman, and J. E. Pontes. "Immunotherapy of renal cell carcinoma." CA: A Cancer Journal for Clinicians 43, no. 3 (May 1, 1993): 177–87. http://dx.doi.org/10.3322/canjclin.43.3.177.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Bukowski, Ronald M. "Renal cell carcinoma: immunotherapy revisited." Therapy 8, no. 4 (July 2011): 335–38. http://dx.doi.org/10.2217/thy.11.41.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Berinstein, Nell. "Immunotherapy of B Cell Lymphoma." Leukemia & Lymphoma 30, sup1 (January 1998): 3–4. http://dx.doi.org/10.3109/10428199809058611.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Park, Dong Soo. "Immunotherapy for Renal Cell Carcinoma." Journal of the Korean Medical Association 51, no. 6 (2008): 569. http://dx.doi.org/10.5124/jkma.2008.51.6.569.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

GASPARI, ANTHONY A., and DANIEL N. SAUDER. "Immunotherapy of Basal Cell Carcinoma." Dermatologic Surgery 29, no. 10 (October 2003): 1027–34. http://dx.doi.org/10.1097/00042728-200310000-00007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Hadzantonis, May, and Helen ONeill. "Dendritic Cell Immunotherapy for Melanoma." Cancer Biotherapy and Radiopharmaceuticals 14, no. 1 (February 1999): 11–22. http://dx.doi.org/10.1089/cbr.1999.14.11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Chang, Kiyuk, Jie-Young Song, and Dae-Seog Lim. "Tolerogenic dendritic cell-based immunotherapy." Oncotarget 8, no. 53 (October 17, 2017): 90630–31. http://dx.doi.org/10.18632/oncotarget.21867.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Peng, Judy, Ranjeny Thomas, and Keith Dredge. "Dendritic Cell Immunotherapy for Melanoma." Reviews on Recent Clinical Trials 1, no. 2 (May 1, 2006): 87–102. http://dx.doi.org/10.2174/157488706776876517.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Polyzoidis, Stavros, and Keyoumars Ashkan. "Dendritic cell immunotherapy for glioblastoma." Expert Review of Anticancer Therapy 14, no. 7 (May 21, 2014): 761–63. http://dx.doi.org/10.1586/14737140.2014.921571.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Golán, Irene, Laura Rodríguez de la Fuente, and Jose Costoya. "NK Cell-Based Glioblastoma Immunotherapy." Cancers 10, no. 12 (December 18, 2018): 522. http://dx.doi.org/10.3390/cancers10120522.

Full text
Abstract:
Glioblastoma (GB) is the most aggressive and most common malignant primary brain tumor diagnosed in adults. GB shows a poor prognosis and, unfortunately, current therapies are unable to improve its clinical outcome, imposing the need for innovative therapeutic approaches. The main reason for the poor prognosis is the great cell heterogeneity of the tumor mass and its high capacity for invading healthy tissues. Moreover, the glioblastoma microenvironment is capable of suppressing the action of the immune system through several mechanisms such as recruitment of cell modulators. Development of new therapies that avoid this immune evasion could improve the response to the current treatments for this pathology. Natural Killer (NK) cells are cellular components of the immune system more difficult to deceive by tumor cells and with greater cytotoxic activity. Their use in immunotherapy gains strength because they are a less toxic alternative to existing therapy, but the current research focuses on mimicking the NK attack strategy. Here, we summarize the most recent studies regarding molecular mechanisms involved in the GB and immune cells interaction and highlight the relevance of NK cells in the new therapeutic challenges.
APA, Harvard, Vancouver, ISO, and other styles
26

Appelbaum, Frederick R. "Haematopoietic cell transplantation as immunotherapy." Nature 411, no. 6835 (May 2001): 385–89. http://dx.doi.org/10.1038/35077251.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Wennhold, Kerstin, Alexander Shimabukuro-Vornhagen, and Michael von Bergwelt-Baildon. "B Cell-Based Cancer Immunotherapy." Transfusion Medicine and Hemotherapy 46, no. 1 (2019): 36–46. http://dx.doi.org/10.1159/000496166.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Büchler, Tomáš. "Immunotherapy for Renal Cell Carcinoma." Klinicka onkologie 28, Suppl 4 (December 15, 2015): 4S64–4S68. http://dx.doi.org/10.14735/amko20154s64.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Poprach, Alexandr, Radek Lakomý, and Tomáš Büchler. "Immunotherapy of Renal Cell Carcinoma." Klinicka Onkologie 30, Suppl 3 (December 14, 2017): 3S55–3S61. http://dx.doi.org/10.14735/amko20173s55.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Corrigan-Curay, Jacqueline, Hans-Peter Kiem, David Baltimore, Marina O'Reilly, Renier J. Brentjens, Laurence Cooper, Stephen Forman, et al. "T-Cell Immunotherapy: Looking Forward." Molecular Therapy 22, no. 9 (September 2014): 1564–74. http://dx.doi.org/10.1038/mt.2014.148.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Urbonas, Vincas, Giedre Smailyte, Greta V. Urbonaite, Audrius Dulskas, Neringa Burokiene, and Vytautas Kasiulevicius. "Natural killer cell-based immunotherapy." Melanoma Research 29, no. 2 (April 2019): 208–11. http://dx.doi.org/10.1097/cmr.0000000000000552.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Kadowaki, Norimitsu, and Toshio Kitawaki. "V. Dendritic Cell-based Immunotherapy." Nihon Naika Gakkai Zasshi 108, no. 7 (July 10, 2019): 1391–96. http://dx.doi.org/10.2169/naika.108.1391.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Stagg, J., and M. J. Smyth. "NK cell-based cancer immunotherapy." Drug News & Perspectives 20, no. 3 (2007): 155. http://dx.doi.org/10.1358/dnp.2007.20.3.1092096.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Colaco, Camilo A. L. S. "Cancer immunotherapy: simply cell biology?" Trends in Molecular Medicine 9, no. 12 (December 2003): 515–16. http://dx.doi.org/10.1016/j.molmed.2003.10.006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Bower, M. "Immunotherapy for renal cell cancer." QJM 91, no. 9 (September 1, 1998): 597–602. http://dx.doi.org/10.1093/qjmed/91.9.597.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Apostolopoulos, Vasso, Geoffrey A. Pietersz, Anastasios Tsibanis, Annivas Tsikkinis, Lily Stojanovska, Ian FC McKenzie, and Stamatis Vassilaros. "Dendritic cell immunotherapy: clinical outcomes." Clinical & Translational Immunology 3, no. 7 (July 18, 2014): e21. http://dx.doi.org/10.1038/cti.2014.14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Buckler, Lee. "Rise of Cell-Based Immunotherapy." Genetic Engineering & Biotechnology News 33, no. 5 (March 2013): 12–13. http://dx.doi.org/10.1089/gen.33.5.05.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

Hirohashi, Y., T. Torigoe, R. Morita, S. Nishizawa, A. Takahashi, S. Inoda, I. Hara, and N. Sato. "Cancer Stem Cell Targeting Immunotherapy." Annals of Oncology 23 (October 2012): xi73. http://dx.doi.org/10.1016/s0923-7534(20)32146-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

Gouttefangeas, Cécile, Arnulf Stenzl, Stefan Stevanović, and Hans-Georg Rammensee. "Immunotherapy of renal cell carcinoma." Cancer Immunology, Immunotherapy 56, no. 1 (May 5, 2006): 117–28. http://dx.doi.org/10.1007/s00262-006-0172-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Bleumer, Ivar, Egbert Oosterwijk, Pieter De Mulder, and Peter F. A. Mulders. "Immunotherapy for Renal Cell Carcinoma." European Urology 44, no. 1 (July 2003): 65–75. http://dx.doi.org/10.1016/s0302-2838(03)00191-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

ENGLEMAN, E. "Dendritic cell-based cancer immunotherapy." Seminars in Oncology 30 (June 2003): 23–29. http://dx.doi.org/10.1016/s0093-7754(03)00229-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Heine, Annkristin, Tobias AW Holderried, and Peter Brossart. "Immunotherapy in renal cell carcinoma." Immunotherapy 1, no. 1 (January 2009): 97–107. http://dx.doi.org/10.2217/1750743x.1.1.97.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

Mickisch, Gerald H. "Immunotherapy of Renal Cell Carcinoma." Urologia Internationalis 63, no. 1 (1999): 16–21. http://dx.doi.org/10.1159/000030413.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Sheng, Iris Y., and Brian I. Rini. "Immunotherapy for renal cell carcinoma." Expert Opinion on Biological Therapy 19, no. 9 (June 12, 2019): 897–905. http://dx.doi.org/10.1080/14712598.2019.1628946.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Berger, C. L., and R. Edelson. "Dendritic cell immunotherapy in malignancies." Drugs of the Future 32, no. 1 (2007): 51. http://dx.doi.org/10.1358/dof.2007.032.01.1064074.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Yang, James C., and Richard Childs. "Immunotherapy for Renal Cell Cancer." Journal of Clinical Oncology 24, no. 35 (December 10, 2006): 5576–83. http://dx.doi.org/10.1200/jco.2006.08.3774.

Full text
Abstract:
For eligible patients, the value of immunotherapy for metastatic clear-cell renal cancer is its curative potential, as demonstrated by long-term follow-up after interleukin-2. Advances in cellular therapies, manipulation of activating and inhibitory receptors on T cells and modification of allotransplantation regimens have all produced new tumor regressions in patients who did not respond to conventional interleukin-2 regimens. It is clear that renal cancer remains one of the most immunoresponsive of human malignancies and that advances in immune modulation are again translating into clinical responses for patients with this disease. As the array of biologic therapies for renal cancer expands with the approval of tyrosine kinase inhibitors, immunotherapy, the only modality that can cure widespread renal cancer, must not be overlooked.
APA, Harvard, Vancouver, ISO, and other styles
47

Szentgyörgyi, E. "Immunotherapy of renal cell carcinoma." International Urology and Nephrology 24, no. 3 (May 1992): 335–36. http://dx.doi.org/10.1007/bf02549544.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Crusinberry, Richard, and Richard D. Williams. "Immunotherapy of renal cell cancer." Seminars in Surgical Oncology 7, no. 4 (July 1991): 221–29. http://dx.doi.org/10.1002/ssu.2980070408.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Unal, Ali. "Dendritic cell Immunotherapy (Cancer Vaccine)." Current Opinion in Biotechnology 22 (September 2011): S24. http://dx.doi.org/10.1016/j.copbio.2011.05.041.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Steinke, John W., and Monica G. Lawrence. "T-cell biology in immunotherapy." Annals of Allergy, Asthma & Immunology 112, no. 3 (March 2014): 195–99. http://dx.doi.org/10.1016/j.anai.2013.12.020.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Cell Immunotherapy' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography